|
||
|
||
| April 25, 2024 | ||
| Search |
| Current Training |
By Course Title |
| Course Catalog |
| By Course Title By Training Partner By Delivery Method |
| Students |
View Registrations/Transcripts |
| About Trainex |
| Overview Contact Us Help! |
| OLEM Training Coordination Team |
| Locate
Team Members Regional/State Training Brochure |
| Other Training Resources |
| EPA Other U.S. Government |
Internet-based seminar
| Hosted by National Institutes of Health, National Institute of Environmental Health Sciences, Superfund Basic Research Program |
This, the third of the three sessions, will feature Mr. Mike Beringer, U.S. EPA Region VII toxicologist, and Dr. Mark Maddaloni, U.S. EPA Region II toxicologist.
Site-specific bioavailability is an important consideration in determining potential threats to human health that are posed by metals-contaminated soils at waste sites. It is important to consider bioavailability because metals may be absorbed to a lesser or greater extent following ingestion of contaminated soils as compared to the fraction absorbed in the studies used to establish toxicity values, such as a reference dose or a cancer slope factor. U.S. EPA's Office of Superfund Remediation and Technology Innovation (OSRTI) has led an effort to develop guidance on evaluating and incorporating bioavailability adjustments into human health risk assessments. The guidance outlines a decision framework for deciding when to collect and incorporate site-specific bioavailability information; recommends a process for documenting the data collection, analysis, and site-specific implementation of a validated method; as well as provides recommended method validation and regulatory acceptance criteria for evaluating alternative methodologies. OSRTI has used these criteria to evaluate two separate methodologies for predicting the relative bioavailability of lead in soil and soil-like materials. OSRTI has determined that both an in vivo swine bioavailability bioassay and an in vitro bioaccessibility assay have sufficiently satisfied these criteria. Thus, they are considered regulatory methodologies appropriate for determining the relative bioavailability of lead for quantitative use in site-specific risk assessments. Mr. Beringer's presentation will summarize the bioavailability guidance document and the basis for OSRTI's decision regarding the two methodologies for predicting lead relative bioavailability.
EPA's bioavailability guidance provides a framework for using bioavailability/bioaccessibility data to inform and refine site specific risk assessments. In the case of lead, which benefits from well-characterized studies on the absorption of this metal when bound to soil, the guidance is highly prescriptive. For many other metals that have limited characterization of their absorption profiles, the guidance is more open to interpretation. The bioavailability guidance will be "test driven" so to speak in a situation where the roadmap is less detailed. In this presentation Dr. Maddaloni will go over a case study involving a RCRA Corrective Action site with arsenic-contaminated soil.
The session will be moderated by Dr. Fred Pfaender, Professor of Environmental Microbiology, Environmental Sciences and Engineering, and Public Health. For general information contact Jean Balent by telephone at 202-566-0832
| Upcoming Events No upcoming events. Archives of past CLU-IN internet seminars are available in the CLU-IN Studio at http://clu-in.org/studio/. You will be able to view the slide and hear an audio stream of the presentation as it occurred.  |
Previous Events (click to view/hide)
|
Live Online Class, Internet Based 
